They program to accomplish this second phase III review by the end of this calendar year. Once the period III is complete, MAPS will make an application for FDA acceptance for MDMA therapy. They foresee FDA acceptance to come in late 2023. When it is actually authorized, the DEA should have three months to re-routine or de-routine MDMA from its lat